Uwm Research Foundation, Inc.

Takeda Gmbh

Hiteshkumar D Jain

James M Cook

Michael Ming-Jin Poe

Ojas A Namjoshi

Jie Yang

Terry S Clayton

Zhi-jian Wang

Sundari K Rallipalli

Yun Teng Johnson

Sarvesh S Patel

Christof Zitt

Andreas Pahl

Torsten Dunkern

Rainer Boer

Angelika Hoffmeyer

Manuela Hessmann

Simone Hartung

Christiane Praechter

Mahindra Makhija

Sandip Gavade

Arati Prabhu

Manojkumar Tiwari

Ashish Keche

Described herein are &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands, pharmaceutical compositions, and methods of use of such ligands and compositions in treatment of anxiety disorders, epilepsy and schizophrenia with reduced sedative and ataxic side effects. In embodiments, such as &#x3b1;3 or &#x3b1;2 or &#x3b1;2/&#x3b1;3 GABAergic receptor subtype selective ligands lack ester linkages and may be thus relatively insensitive to hydrolysis by esterases.

GABAergic receptor subtype selective ligands and their uses

The compounds of formula (1) in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

EP2 receptor agonists

Gabaergic receptor subtype selective ligands and their uses

Growing community of inventors

Mumbai, India

Hiteshkumar D Jain